Serum markers of type I collagen synthesis and degradation in amyotrophic lateral sclerosis

European Neurology

Volumn 44, Issue 1, 2000, Pages 49-56

  Ono, Seiitsu ^a   Imai, Takashi ^b   Shimizu, Natsue ^a   Nakayama, Megumi ^a   Yamano, Takahiko ^a   Tsumura, Mayumi ^c  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b National Chiba Higashi Hospital   (Japan)

^c BML   (Japan)

Author keywords

Amyotrophic lateral sclerosis; Collagen content; Skin; Type l collagen

Indexed keywords

COLLAGEN TYPE 1; PEPTIDE; PROCOLLAGEN;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; PATHOGENESIS; PRIORITY JOURNAL; SKIN BIOPSY;

EID: 0033934650     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000008193     Document Type: Article

References (45)

1. Ono S, Toyokura Y, Mannen T, Ishibashi Y: Amyotrophic lateral sclerosis: Histological, histochemical, and ultrastructural abnormalities of skin. Neurology 1986;36:948-956.
2. Ono S, Imai T, Takahashi K, Jinnin K, Yamano T, Nagao K, Shimizu N, Yamauchi M: Decreased type IV collagen of skin and serum in patients with amyotrophic lateral sclerosis. Neurology 1998;51:114-120.
3. Ono S, Yamauchi M: Collagen cross-linking of skin in patients with amyotrophic lateral sclerosis. Ann Neurol 1992;31:305-310.
4. Ono S, Yamauchi M: Amyotrophic lateral sclerosis: Increased solubility of skin collagen. Neurology 1992;42:1535-1539.
5. Ono S, Imai T, Munakata S, Takahashi K, Kanda F, Hashimoto K, Yamano T, Shimizu N, Nagao K, Yamauchi M: Collagen abnormalities in the spinal cord from patients with amyotrophic lateral sclerosis. J Neurol Sci 1998;160:140-147.
6. Triffitt JT: The special proteins of the bone tissue. Clin Sci 1987;72:399-408.
7. Hunzelmann N, Risteli J, Risteli L, Sacher C, Vancheeswaran R, Black C, Krieg T: Circulating type 1 collagen degradation products: A new serum marker for clinical severity in patients with scleroderma. Br J Dermatol 1998;139: 1020-1025.
8. Prockop DJ, Kivirikko KI, Tuderman L, Guzman NA: The bio-synthesis of collagen and its disorders (first of two parts). N Engl J Med 1979;301:13-23.
9. Miyahara M, Njieha FK, Prockop DJ: Formation of collagen fibrils in vitro by cleavage of procollagen with procollagen proteinases. J Biol Chem 1982;257:8442-8448.
10. Melkko J, Niemi S, Risteli L, Risteli J: Radioimimmoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990;36:1328-1332.
11. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L: Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin Chem 1993;39:635-640.
12. Parfitt AM, Simon LS, Villanueva AR, Krane SM: Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 1987;2:427-436.
13. Brooks BR: El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994; 124(suppl):96-107.
14. Caroscio JT, Cohen JA, Zawodniak J, Takai V, Shapiro A, Blaustein S, Mulvihill MN, Loucas SP, Gudesblatt M, Rube D: A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis. Neurology 1986;36:141-145.
15. Patten BM, Harati Y, Acosta L, Jung SS, Feimus MT: Free amino acid levels in amyotrophic lateral sclerosis. Ann Neurol 1978;3:305-309.
16. Minor RR: Collagen metabolism: A comparison of diseases of collagen and diseases affecting collagen. Am J Pathol 1980;98:225-280.
17. Streuyer L: Biochemistry. New York, Freedman, 1988.
18. Yamauchi M, Woodley DT, Mechanic GL: Aging and cross-linking ot skin collagen. Biochcm Biophys Res Commun 1988;152:898-903.
19. Ono S, Mechanic GL, Yamauchi M: Amyotrophic lateral sclerosis: Unusually low content of collagen in skin. J Neurol Sci 1990;100:234-237.
20. Smedsrød B, Melkko J, Risteli L, Risteli J: Circulating C-terminal propeptide of type 1 procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 1990;271:345-350.
21. Hassager C, Jensen LT, Johansen JS, Riis BJ, Melkko J, Podenphant J, Risteli L, Christiansen C, Risteli J: The carboxy-terminal propeptidc of type I procollagen in serum as a marker of bone formation: The effect of nandrolone deeanoate and female sex hormones. Metabolism 1991;40:205-208.
22. Akimoto S, Akakura K, Shimazaki J: Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer. Jpn J Clin Oncol 1996;26:157-163.
23. Joerring S, Jensen LT, Andersen GR, Johansen JS: Types I and III procollagen extension peptides in serum respond to fracture in humans. Arch Orthop Trauma Surg 1992;111:265-267.
24. Li F, Iqbal J, Wassif W, Kaddam I, Moniz C: Carboxyterminal propeptide of type I procollagen in osteomalacia. Calcif Tissue Int 1994; 55:90-93.
25. Simon LS, Krane SM, Wortman PD, Krane IM, Kovitz KL: Serum levels of type I and III procollagen fragments in Paget's disease of bone. J Clin Endocrinol Metab 1984;58:110-120.
26. Guañabens N, Parés A, Alvarez L, Martinez de Osaba MJ, Monegal A, Perris P, Ballesta AM, Rodes J: Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J Bone Miner Res 1998;13:731-738.
27. Savolainen ER, Goldberg B, Leo MA, Velez M, Lieber CS: Diagnostic value of serum procollagen peptide measurements in alcoholic liver disease. Alcohol Clin Exp Res 1984;8:384-389.
28. Kikuchi K, Ihn H, Sato S, Igarashi A, Soma Y, Ishibashi Y, Takehara K: Serum concentration of procollagen type I carboxyterminal propeptide in systemic sclerosis. Arch Dermatol Res 1994;286:77-80.
29. Kikuchi K, Sato S, Kadono T, Ihn H, Takehara K: Serum concentration of procollagen type 1 carboxyterminal propeptide in localized scleroderma. Arch Dermatol 1994;130:1269-1272.
30. Diez J.,Laviades C, Mayor G, Gil MJ, Monreal I: Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation 1995; 91:1450-1456.
31. Saggese G, Bertelloni S, Baroncceli GI, Nero GD: Serum levels of carboxyterminal propeptide of type I procollagen in healthy children from 1st year of life to adulthood and in metabolic bone diseases. Eur J Pediatr 1992;151: 764-768.
32. Tähtela R, Thölix E: Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy- and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Anticancer Res 1996;16:2289-2293.
33. Legovini P, De Menis E, Da Rin G, Roiter I, Breda F, Artuso V, Divirgilio R, Conte N: Increased serum levels of carboxyterminal propeptide of type I collagen (PICP) in hyperthyroidism. Horm Metab Res 1994;26:334-337.
34. Oikarinen A, Autio P, Vuori J, Vaananen K, Risteli L, Kiistala V, Risteli J: Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen. Br J Dermatol 1992;126: 172-178.
35. Miyakawa M, Tsushima T, Demura H: Carbosy-terminal propeptide of type 1 procollagen (PICP) and carboxy-terminal telopeptide of type 1 collagen (ICTP) as sensitive markers of bone metabolism in thyroid disease. Endocr J 1996;43:701-708.
36. Elomaa I, Virkkunen P, Risteli L, Risteli J: Serum concentration of the cross-linked ear-boxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 1992;66:337-341.
37. Hansen M, Hørslev-Petersen K. Stoltenberg M, Lorenzen I, Risteli L, Risteli J: Type I collagen metabolism in rheumatoid arthritis. Effect of a single pulse of methylprednisolone. Br J Rheumatol 1992;31(suppl 2):129.
38. Hakala M, Risteli L, Manelius J, Nieminen P, Risteli J: Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis. Ann Rheum Dis 1993;52:866-869.
39. Heickendorff L, Zachariac H, Bjerring P. Hallkier-Sorensen L, Sondergaard K: The use of serologic markers for collagen synthesis and degradation in systemic sclerosis. J Am Acad Dermatol 1995;32:584-588.
40. Kylmälä T, Tammela T, Risteli L, Risteli J, Tsube T, Elomaa I: Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer 1993;29A:821-825.
41. Ricard-Blum S, Chossegros P, Guerret S, Trepo C, Grimaud JA, Chevallier M: The carboxy-terminal cross-linked telopeptide of type 1 collagen (ICTP) is a potential serum marker of ongoing liver fibrosis. Clin Chim Acta 1996; 248:187-195.
42. Wenisch C, Bankl HC, Schönthal E, Myskiw D, Presterl E, Runpold H, Graninger W: Serum levels of the carboxy-terminal cross-linked telopeptide of type I collagen and laminin are elevated in Graves' disease but not in toxic nodular goiter. Clin Immunol Immunopathol 1995; 75:225-230.
43. Katagiri M, Ohtawa T, Fukunaga M, Harada T: Evaluation of bone loss and the serum markers of bone metabolism in patients with hyperparathyroidism. Jpn J Surg 1995;25:598-604.
44. Kahaleh MB, Sultany GL, Smith EA, Huffstuttcr JE, Loadholt CB, LeRoy EC: A modified scleroderma skin scoring method. Clin Exp Rheumatol 1986;4:367-369.
45. Ono S, Imai T, Takahashi K, Jinnai K, Kanda F, Fukuoka Y, Hashimoto K, Shimizu N, Nagao K: Alteration in amino acids in motor neurons of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci 1999;167:121-126.